• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Marton Laurence exercised 20,480 shares at a strike of $0.15, increasing direct ownership by 45% to 66,164 units (SEC Form 4)

    5/6/25 4:10:20 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Marton Laurence

    (Last) (First) (Middle)
    C/O RENOVORX, INC.
    2570 W EL CAMINO REAL, SUITE 320

    (Street)
    MOUNTAIN VIEW CA 94040

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RenovoRx, Inc. [ RNXT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/02/2025 M(1) 20,480 A $0.15 66,164 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.15 05/02/2025 M(1) 20,480 (2) 10/14/2025 Common Stock 20,480 $0.00 0 D
    Explanation of Responses:
    1. Represents the reporting person's cash exercise of an outstanding stock option into shares of common stock, with no sale of such shares of common stock.
    2. Shares subject to the option are fully vested and immediately exercisable.
    /s/ Laurence J. Marton 05/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RNXT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    SEC Filings

    View All

    SEC Form 8-K filed by RenovoRx Inc.

    8-K - RenovoRx, Inc. (0001574094) (Filer)

    8/14/25 5:00:57 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by RenovoRx Inc.

    SCHEDULE 13G/A - RenovoRx, Inc. (0001574094) (Subject)

    8/14/25 4:42:08 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by RenovoRx Inc.

    10-Q - RenovoRx, Inc. (0001574094) (Filer)

    8/14/25 4:08:03 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on RenovoRx with a new price target

    Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

    11/1/21 11:49:10 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on RenovoRx with a new price target

    Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

    10/6/21 8:24:28 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Agah Ramtin bought $29,400 worth of shares (21,000 units at $1.40), increasing direct ownership by 3% to 734,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    6/9/25 6:03:27 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/17/25 6:10:32 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Bagai Shaun bought $6,821 worth of shares (7,500 units at $0.91), increasing direct ownership by 2% to 320,040 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/16/25 6:08:22 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bagai Shaun

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    7/3/25 4:45:33 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Agah Ramtin

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    7/3/25 4:45:34 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Clinical Officer Gentry Leesa

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    7/3/25 4:45:31 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

    Revenue from RenovoCath® device totaled over $400,000 for the Second Quarter 2025 As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents Management to host conference call today at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced its financial results and business update to shareholders for the second quarter ended June 30, 2025. "We are pleased to report second quarter 2025 revenue of over $400,000. This growth highlights the strong clinical need and market demand for our

    8/14/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

    RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat orders of RenovoCath for interventional radiology procedures RenovoRx hires Senior Director of Sales and Market Development to coordinate, execute, and expand commercialization strategy MOUNTAIN VIEW, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery devic

    8/6/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

    Several Esteemed Cancer Centers to Commence Patient Enrollment Before the End of September The Registry Study, Known as PanTheR, will Expand the Safety and Performance Data of the FDA-Cleared RenovoCath® Device, and its Associated Survival Outcomes in Patients Diagnosed with Solid Tumors Cancer Centers in the Registry Study will Purchase RenovoCath Devices from RenovoRx RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461). The initiation of t

    7/28/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Financials

    Live finance-specific insights

    View All

    RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

    Revenue from RenovoCath® device totaled over $400,000 for the Second Quarter 2025 As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents Management to host conference call today at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced its financial results and business update to shareholders for the second quarter ended June 30, 2025. "We are pleased to report second quarter 2025 revenue of over $400,000. This growth highlights the strong clinical need and market demand for our

    8/14/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

    RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced it will host its second quarter 2025 financial results and business highlights conference call on August 14, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. On the call, RenovoRx management is expected to discuss the latest developments and achievements for the Company's ongoing RenovoCath device commercialization efforts and for the Company's pivotal Phase III TIGeR-P

    7/14/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

    Q1 2025 RenovoCath® Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of $14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of the Ongoing Phase III TIGeR-PaC Clinical Trial Completion of the TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Company to Host Conference Call at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializ

    5/15/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

    LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

    6/10/24 8:30:00 AM ET
    $IMMX
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Closes $6.1 Million Private Placement

    With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

    1/29/24 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

    RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

    11/16/23 8:35:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

    SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

    2/14/23 4:51:34 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    4/14/22 2:24:24 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    2/14/22 6:33:04 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care